Contact Us
Click here to contact Felicity Thomas,editor.
June 11, 2014
Ocular inflammation Once daily solution achieves zero-to-trace cell severity Bromfenac ophthalmic solution 0.07% (Pro-Lensa, Bausch + Lomb) used once a day results in zero-to-trace (0–5 cells) cell severity in the anterior chamber following cataract surgery with implantation of a posterior chamber IOL, according to newly published research. More...
AMD development risk Vasodilator use linked to AMD development Taking vasodilators may increase the risk of developing early-stage age-related macular degeneration (AMD), according to a study published online. More...
Glaucoma therapy Positive CHMP opinion for glaucoma drops The CHMP of the EMA has issued a positive opinion for brinzolamide 10 mg/mL and brimonidine tartrate 2 mg/mL eye drops suspension to decrease elevated IOP in adult patients with open-angle glaucoma or ocular hypertension, for whom monotherapy provides insufficient IOP reduction. More...
Products in Practice Issue 3
Real world experience of leading ophthalmic products.
Read more:
Ranibizumab leading the anti-VEGF evolution
Considerations and new perspectives in anti-VEGF therapy.
Read more:
